Flow Cytometer to Extend Laboratory Capabilities

描述(由申请人提供)：细胞分析设施(CAF)，内布拉斯加大学医学中心(UNMC)的核心设施，申请581,998.00美元购买高端流式细胞仪，用于分析多参数研究样本。该仪器将是由BD Bioscience公司根据我们的规格制造的6台激光、19个探测器的LSR II流式细胞仪。现有的LSR II已经100%认购，是实验室中唯一可用于实验的分析仪器，使用该地区超过6个同时参数，并且没有备份。样本处理的延迟目前是一个问题，因为基础和临床研究项目的研究人员对该仪器的需求很高。这种仪器的停机时间虽然很少，但对这些调查人员来说可能会产生灾难性的影响。拟议的仪器将放置在CAF中，由经验丰富的人员管理，包括主任库辛斯基博士，他为该设施提供专门支持。确定的主要用户组由九名NIH资助的研究人员和一个确定的两人小组组成，他们需要大部分当前仪器时间(1168小时，数据未显示)，将他们的工作转移到新仪器将允许他们和其他目前使用现有LSR II的用户扩大对仪器的访问。LSRII的当前用户总数为31人，包括主要和次要用户，2010年有85名独立调查人员使用过该设施。将该仪器添加到实验室将促进再生医学、转化研究和癌症生物学领域的进展，以及免疫学、微生物学和艾滋病的进一步基础研究。这些领域的发现将为患者带来更好的治疗、治愈和结果。

DESCRIPTION (provided by applicant): The Cell Analysis Facility (CAF), a core facility of the University of Nebraska Medical Center (UNMC), is requesting $581,998.00 to purchase a high end flow cytometer for the analysis of multi-parametric research samples. This instrument will be a 6 laser, 19 detector LSR II flow cytometer manufactured by BD Bioscience according to our specifications. The existing LSR II is 100% subscribed and is the only analysis instrument in the laboratory available for experiments utilizing more that 6 simultaneous parameters in the area and is without backup. Delays in sample processing are currently an issue as the instrument is in high demand from investigators with both basic and clinical research programs. Down time, though rare, for this instrument could have disastrous implications for these investigators. The proposed instrument will be housed in the CAF and managed by experienced personnel including the director, Dr. Kuszynski who provides dedicated support for the facility. The identified Major User Group consists of nine NIH funded investigators and an identified minor group of two who require most of the current instrument time (1168 hrs, data not shown) and shifting their work to the new instrument will allow for expanded access to the instrumentation for them and additional users who currently use the existing LSR II. The total number of current users for the LSRII is 31 including the major and minor users and 85 independent investigators have used the facility in 2010. Addition of this instrument to the laboratory will foster advances n the areas of regenerative medicine, translational research, and cancer biology as well as further basic research in immunology, microbiology and AIDS. Discoveries in these areas will lead to better treatments, cures and outcomes for patients.